# NIVOTHYM (NCT03134118)

> Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

No report yet. It can be ordered.

- Drugs tested: nivolumab
- Indication: previously treated type B3 thymoma and thymic carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03134118
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Conditions: Thymoma Type B3; Thymic Carcinoma
- Interventions: Nivolumab
- Enrollment: 55
- Primary outcome: Progression Free Survival Rate (PFSR) at month 6

## Indexed commentary on NIVOTHYM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nivothym-nct03134118

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03134118", "email": "<work email>"}; the inbox owner confirms by the emailed link.